The Endpoints 11: How we picked 2026's most exciting biotech startups

Choosing the Endpoints 11 biotech startups was more challenging this year than ever before. The process of identifying the year's most intriguing companies involves extensive research and debate by the reporters and editors over the course of the summer. It typically begins in late spring, but this year was particularly difficult due to the secrecy surrounding biotech companies.

Many are hesitant to disclose their research due to fears of competition from both domestic and foreign rivals. However, this also contributes to the uniqueness of the Endpoints 11 list, as many of the companies featured in Boston later this month will be sharing their science for the first time. This event serves to highlight the risk-takers at the forefront of innovation and showcases some of their groundbreaking work.

If you wish to meet the companies that the panel believes will shape the next few years, attend the gala evening on September 24 in Boston. The winners will be announced, and they come from various fields such as cell therapy, AI, and gene therapy. Additionally, Wyss Institute founding director Don Ingber will engage in an intimate conversation with Endpoints News science correspondent Ryan Cross, discussing the significance of fostering fundamental science and unconventional ideas to maintain the competitiveness of America's biotech industry.